Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Up 378.3% in May

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Rating) saw a large increase in short interest in May. As of May 15th, there was short interest totalling 310,400 shares, an increase of 378.3% from the April 30th total of 64,900 shares. Based on an average daily trading volume, of 1,897,300 shares, the short-interest ratio is presently 0.2 days.

Bayer Aktiengesellschaft Price Performance

BAYRY traded down $0.18 on Friday, hitting $14.31. 740,021 shares of the company were exchanged, compared to its average volume of 788,487. The firm has a fifty day simple moving average of $15.79 and a two-hundred day simple moving average of $14.98. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.16 and a quick ratio of 0.77. Bayer Aktiengesellschaft has a 12 month low of $11.41 and a 12 month high of $18.01.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Rating) last released its quarterly earnings results on Thursday, May 11th. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.24. Bayer Aktiengesellschaft had a return on equity of 18.53% and a net margin of 6.06%. The company had revenue of $15.44 billion for the quarter, compared to analyst estimates of $15.76 billion. Equities research analysts forecast that Bayer Aktiengesellschaft will post 1.88 earnings per share for the current year.

Bayer Aktiengesellschaft Increases Dividend

The firm also recently disclosed a dividend, which was paid on Monday, May 15th. Investors of record on Wednesday, May 3rd were issued a $0.4302 dividend. This is an increase from Bayer Aktiengesellschaft’s previous dividend of $0.37. The ex-dividend date was Tuesday, May 2nd. This represents a dividend yield of 2.58%. Bayer Aktiengesellschaft’s dividend payout ratio (DPR) is presently 54.88%.

Bayer Aktiengesellschaft Company Profile

(Get Rating)

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents.